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Abstract
In proliferating myoblasts, muscle specific genes are silenced by epigenetic modifications at their promoters, including
histone H3K9 methylation. Derepression of the promoter of the gene encoding the myogenic factor myogenin (Myog) is key
for initiation of muscle differentiation. The mechanism of H3K9 demethylation at the Myog promoter is unclear, however.
Here, we identify an isoform of the histone demethylase JMJD2A/KDM4A that lacks the N-terminal demethylase domain
(DN-JMJD2A). The amount of DN-JMJD2A increases during differentiation of C2C12 myoblasts into myotubes. Genome-wide
expression profiling and exon-specific siRNA knockdown indicate that, in contrast to the full-length protein, DN-JMJD2A is
necessary for myotube formation and muscle-specific gene expression. Moreover, DN-JMJD2A promotes MyoD-induced
conversion of NIH3T3 cells into muscle cells. ChIP-on-chip analysis indicates that DN-JMJD2A binds to genes mainly involved
in transcriptional control and that this binding is linked to gene activation. DN-JMJD2A is recruited to the Myog promoter at
the onset of differentiation. This binding is essential to promote the demethylation of H3K9me2 and H3K9me3. We
conclude that induction of the DN-JMJD2A isoform is crucial for muscle differentiation: by directing the removal of
repressive chromatin marks at the Myog promoter, it promotes transcriptional activation of the Myog gene and thus
contributes to initiation of muscle-specific gene expression.
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Introduction
In eukaryotes, the genome is organized into a highly ordered
structure called chromatin, composed of DNA and histone
proteins. Chromatin architecture is dynamic and regulated in
part by enzymes that mediate covalent post-translational modifi-
cations of the N-terminal tails of histones. These so-called
epigenetic modifications of histones control the expression of the
genes they are associated with, thus they are crucial in determining
cell fate decisions.
Enzymes that remove methyl groups from lysine residues in
histones (histone lysine demethylases, KDMs) were discovered
only recently and are highly specific for particular lysine residues,
similarly to histone lysine (K) MethylTransferases (KMT) [1]. The
first discovered demethylase, LSD1, is a flavin-monoamine oxidase
that demethylates mono- or dimethylated lysine residues 4 and 9
in histone H3 (H3K4 and H3K9) [2]. The Jumonji domain-
containing demethylases catalyze protein demethylation through a
hydroxylation reaction requiring iron and 2-oxoglutarate as co-
factors. The JMJD2/KDM4 subfamily (JMJD2A, B, C and D)
specifically demethylates H3K9 and H3K36 either di- or tri-
methylated [3–7].
Few regulatory functions have been described for the JMJD2
family. JMJD2C was described as a co-activator of androgen
responsive genes in prostate cancer cells and of the Nanog gene in
ES cells [8–11]. By contrast, mainly co-repressor activities have
been reported for JMJD2A: as a component of the nuclear
receptor co-repressor (N-CoR) complex involved in the repression
of the ASCL2 gene [12], a function that requires its demethylase
activity [6], and associated with histone deacetylases and the
retinoblastoma protein Rb to repress E2F-regulated promoters (in
this case, the role of its demethylase activity was not investigated)
[13]. JMJD2A was also suggested to be a co-activator of androgen
receptor-dependent gene transcription [14], but this is controver-
sial since another group claimed that this function is specific to
JMJD2C [8].
During skeletal muscle differentiation, signaling to chromatin is
important to drive the correct temporal expression of muscle-
specific genes [15]. During this process, myoblasts cease prolifer-
ating and fuse into multinucleated myotubes; at the same time,
muscle specific genes begin to be transcribed and cell cycle-
associated genes are repressed. The b-HLH family of myogenic
transcriptionfactors (includingMyoD,Myf5,myogeninandMRF4)
and the MEF2 factors play key roles in controlling muscle-specific
gene expression. In response to appropriate differentiation signals,
MyoD, which is expressed in myoblasts, turns on the differentiation
program by first activating expression of the gene encoding
myogenin (Myog). Then, in cooperation with myogenin, it induces
the expression of many other muscle specific genes [16]. MyoD and
MEF2 factors act in concert with histone acetyltransferases and
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modifying the architecture of chromatin at specific loci.
Whereas the role of histone acetylation in the control of muscle-
specific gene expression has been studied extensively (reviewed in
[17]), less is known about the role of histone methylation in this
process. The Polycomb group protein Ezh2, a methyltransferase,
is involved in inhibiting muscle differentiation by methylating
H3K27 at muscle-specific genes regulatory elements in myoblasts
[18]. The role of Ezh2 is counteracted by the histone demethylase
UTX, which demethylates H3K27 to participate in the activation
of muscle-specific loci during differentiation [19]. Ash2L methyl-
transferase-containing complexes also contribute to this activation
by methylating H3K4 [20]. In addition to H3K27, H3K9
methylation also participates in Myog repression, ensuring that
cells do not differentiate prematurely. The Myog promoter is
hypermethylated on H3K9 in myoblasts and demethylated in
myotubes concomitant with transcriptional activation of the Myog
gene [21]. The histone methyltransferase Suv39h1 is responsible
for the establishment of this repressive epigenetic mark in
myoblasts, and is targeted to the Myog promoter by interacting
with MyoD [22,23]. The mechanism leading to H3K9 demeth-
ylation of the Myog promoter at the onset of differentiation has not
been studied extensively, however.
Here, we identify a new isoform of JMJD2A in which the N-
terminal demethylase domain has been deleted (DN-JMJD2A). This
isoform is upregulated at the onset of myoblast differentiation into
myotubes and is essential for this process. By using a genome-wide
approach, we show that DN-JMJD2A acts as a transcriptional co-
activator for many genes induced specifically during skeletal muscle
differentiation. Furthermore, we demonstrate that DN-JMJD2A binds
directly to the Myog promoter to regulate H3K9 methylation, thus
allowing Myog expression and promoting myotube differentiation.
Results
A short isoform of JMJD2A is upregulated during muscle
differentiation
To investigate the role of the histone demethylase JMJD2A in
muscle differentiation, we first characterized expression of JMJD2A
mRNA in a mouse myoblast cell line, C2C12, which has been used
extensively asa model ofskeletalmuscledifferentiation.C2C12 cells
differentiated into myotubes expressing muscle specific genes within
three daysafter additionofdifferentiating medium,asdemonstrated
by the strong induction of mRNAs from the Myog and muscle
creatine kinase (Ckm) genes (Figure 1A). By contrast, JMJD2A
mRNA, as quantified by RT-qPCR using primers located in its
39end, was expressed at relatively constant levels during this time
(Figure 1A). As shown in Figure 1A (upper panel), JMJD2A mRNA,
quantified by RT-qPCR using primers located in its 39end, is
expressed at relatively constant levels during the course of C2C12
cells differentiation. We also analyzed JMJD2A protein levels by
western blotting the cells with an antibody directed against the C-
terminal part of JMJD2A (a-Cter-JMJD2A). In addition to the full-
lengthprotein,whoselevelsremainedconstant,wenoticed asmaller
isoform of about 60 kDa in differentiating C2C12 cells (Figure 1B).
In primary human satellite cells, differentiation was also accompa-
nied by the appearance of a polypeptide of very similar apparent
molecular weight to that observed in C2C12 cells (Figure 1C).
Thesedatasuggesttheexistenceofa newisoform ofJMJD2Awhose
expression increases during muscle terminal differentiation. Note
that this isoform can also be detected in proliferating C2C12 cells
when the blots are exposed for longer times (data not shown). To
prove that this isoform was derived from JMJD2A, and to gain
insights into the mRNA producing it, we transfected differentiating
C2C12 cells with exon-specific siRNAs against various parts of
JMJD2A mRNA (Figure 1D). As expected, all siRNAs interfered
with expression of the full-length protein (Figure 1E). Strikingly,
whereas the siRNAs against exons 9, 10, 11, 16 and 22 of JMJD2A,
also decreased expression of the short isoform, those against exon 3
did not (Figure 1E), This suggests that the small isoform of JMJD2A
is produced from a mRNA derived from the JMJD2A gene but
lacking the 59 end of the full-length JMJD2A mRNA.
The short isoform is produced from an mRNA that
initiates within the coding region of the JMJD2A gene
The Genbank database contains a description of a small mRNA
(AK136085.1) whose transcription starts inside the coding sequence
of the for JMJD2A gene and which is identical to the full-length
mRNA sequence from the end of exon 9 to the 39 end of JMJD2A
variant 1 (NM_001161823.1; see Figure S1 for an alignment). The
siRNA that targeted the beginning of exon 9 of JMJD2A inhibited
production of the small isoform described in Figure 1, however,
indicating that the mRNA that encodes the small isoform differs
from AK136085.1. To identify the 59end of this mRNA, we
performed rapid amplification of 59 complementary DNA ends
(59RACE) using total mRNA isolated from differentiated C2C12
cells. We designed the primers according to the effects observed on
the short isoform expression using exon-specific siRNAs (see
Figure 1D and 1E) and used them to isolate 50 clones containing
parts of JMJD2A mRNA, which we then sequenced (Figure 2A).
Among these, eight clones were identical to the 59 end of the full-
length sequence described in Genbank (NM_001161823.1). The
transcription start site (TSS) of NM_001161823.1 was designated as
+1 relative to this sequence. Fifteen clones started downstream of
this TSS at a position located in the first intron of JMJD2A. Since
the ATG corresponding to the full-length protein is present in exon
2, this latter mRNA is also likely to produce the full-length JMJD2A
protein. Twenty seven clones initiated inside the coding region at
the59 end ofexon 8,ofwhich16 had a TSSat +977and 11 at+980.
Thus, a significant proportion of JMJD2A mRNAs initiate at the
beginning of exon 8 in differentiating C2C12 cells (see Figure S1 for
alignment of sequences).
Author Summary
Gene expression is regulated in part by so-called
‘‘epigenetic’’ mechanisms—modifications of the DNA itself
or of proteins associated with DNA (such as histones). We
have studied an enzyme that affects these histone
modifications—the histone demethylase JMJD2A—and
its role in muscle differentiation. Muscle differentiation is
tightly controlled during the development of the organism
to ensure that muscle forms at the right place and at the
right time. Muscle precursor cells are prevented from
differentiating by silencing of a ‘‘master gene’’ of muscle
differentiation called Myog. This silencing is brought about
by specific epigenetic modifications of the Myog gene that
are removed when the precursor cell receives a signal to
differentiate. Here, we have discovered a new isoform of
JMJD2A that is upregulated during muscle differentiation
and that is required for activation of Myog. Binding of this
JMJD2A isoform to the Myog gene is probably a crucial
step in inducing muscle differentiation. Our findings thus
uncover the existence of a second isoform of the histone
demethylase JMJD2A important for muscle differentiation
and suggest that the balance between JMJD2A isoforms is
important for controlling the fate of muscle precursor cells.
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analysed their expression in proliferating cells and in differentiat-
ing cells by qPCR with primers located immediately upstream of
nucleotide +977 (Nu977, primer pairs 1 and 2) or immediately
downstream of Nu977 (primer pairs 3 and 4; Figure 2B). We found
that the signal observed with primer pairs 3 and 4 was 20–30%
Figure 1. Expression of JMJD2A during muscle differentiation. (A) The expression of JMJD2A, Myog, Ckm and gapdh mRNA was measured by
RT-qPCR of RNA from C2C12 cells kept in growth medium (0 h) or shifted to differentiation medium for 24, 48 or 72 hours. mRNA levels were
standardized to gapdh mRNA levels, and calculated relative to 1 in proliferating cells. (B) Western blots of total protein extracts from C2C12 cells
before (0 h) or after 24, 48 or 72 hours of differentiation analyzed for the presence of JMJD2A (a-Cter antibody), myogenin, myosin heavy chain
(MHC) and a-tubulin (as a control for equal loading). The asterisk (*) indicates a non-specific band (as indicated by subsequent analysis using siRNAs
and through the use of other antibodies; data not shown). JMJD2A-specific bands are indicated by arrowheads. Note that we show two different
exposures of this western blot (C)Western blots of total protein extracts from human skeletal myoblasts (Hskm) in proliferating (GM) or differentiated
conditions (MT), and from differentiating C2C12 cells (left lane) analyzed for expression of JMJD2A (a-Cter antibody), myosin heavy chain (MHC) and
a-tubulin. JMJD2A-specific bands are indicated by arrowheads. The asterisk (*) indicates a non-specific band. (D) Schematic representation of JMJD2A
mRNA(NM_001161823.1) indicating the positions of hybridisation of the siRNAs used in this study. The black bars indicate the siRNAs that knockdown
only full-length JMJD2A protein expression whereas the green bars indicate the siRNAs that knockdown expression of both the full-length and the
short isoform. The siRNAs are named according to the exon they target and the position in the exon (e.g. sie3-1 for the most upstream siRNA
targeting exon 3). (E) C2C12 cells were transfected with siRNAs targeting both isoforms of JMJD2A (e9, e10, e16 and e22), only full-length JMJD2A (e3-
1 and e3-2) or control siRNA (ctl). After 24 hours of differentiation, western blots of total protein extracts were analysed for JMJD2A (a-Cter antibody)
and a-tubulin. The panels on the left include a serial dilution (1, K and J) of extracts from cells transfected with the control siRNA.
doi:10.1371/journal.pgen.1001390.g001
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differentiated cells, indicating that DN1-JMJD2A and DN2-
JMJD2A mRNAs are expressed at about 20% of the amount of
the full-length mRNAs. In addition, the expression of these
mRNAs slightly decreased during differentiation relative to the
full-length (FL)-JMJD2A mRNA (Figure 2B).
To test if the small mRNA (DN1/2-JMJD2A) could encode the
shorter of the two proteins we observed above (see Figure 1), we
cloned the JMJD2A cDNA starting at nucleotide +977 and
expressed it in proliferating and differentiating C2C12 cells. In
cells kept in growth medium (GM) or shifted into differentiation
medium for 24 h (DM), overexpression of this cDNA under the
control of the CMV promoter led to production of various
polypeptides with apparent molecular weights of 115, 85 and
around 60 kDa (denoted 1–3 respectively, in Figure 2C). The
60 kDa polypeptides comprised two bands in proliferating
myoblasts and three in differentiating cells, the fastest of these
bands co-migrated exactly with the endogenous JMJD2A short
isoform (seen in lane 5). These 60 kDa polypeptides were more
abundant in differentiating cells; they represent about 40% of the
total in differentiating cells compared to only 5% in proliferating
myoblasts (Figure 2C, right). This suggests that the JMJD2A
mRNA that initiates at nucleotide 977 directs production of a
protein corresponding to the endogenous JMJD2A small isoform
preferentially in differentiating cells.
Several potential initiation codons (ATG) are present in the
Nu977 mRNA sequence (Figure 2). To characterize further the
small isoform of JMJD2A, we constructed deletion mutants of
JMJD2A and expressed them in C2C12 cells. The constructs were
named according to their first methionines: pCDNA3-JMJD2A-
M317 (data not shown), pCDNA3-JMJD2A-M427 and pCDNA3-
JMJD2A-M584. A protein initiating at Met584 (JMJD2A-M584)
migrated close to the endogenous small isoform (Figure 2E). Taken
together with the data obtained by using isoform-specific siRNAs
(Figure 1), these findings indicate that the small isoform is
produced from an mRNA initiating within the JMJD2A gene.
This shorter isoform lacks the N-terminal sequences of JMJD2A
and thus lacks the demethylase domain; hereafter we call this
isoform DN-JMJD2A.
DN-JMJD2A is required for C2C12 cell differentiation
To investigate the role of DN-JMJD2A, we performed genome-
wide expression profiling of C2C12 cells following transfection
with siRNAs against both isoforms of JMJD2A. (Since the mRNA
encoding DN-JMJD2A initiates in an exon, it is impossible to
design specific siRNAs for this isoform). We transfected C2C12
cells with siRNAs that target exon 9 or exon 10 (sie9 and sie10)
and maintained them in proliferation medium for 24 h before
shifting them to differentiation medium for 36 hours. (Important-
ly, these siRNA did not affect JMJD2B and JMJD2C mRNAs;
Figure S2). Total mRNA was hybridized onto the GeneChip
Mouse Gene 1.0 ST Affymetrix microarray. Genes were
considered as deregulated upon JMJD2A knockdown, as com-
pared to a control siRNA (p-value ,0.05), when the calculated
average fold change was greater than 1.5 in three independent
experiments with two independent siRNAs. We found that the
expression of 89 genes was affected by JMJD2A knockdown, of
which 68 were downregulated (Figure 3A) (See Table S1 for the
list of JMJD2A-regulated genes). Gene ontology (GO) analysis
using DAVID software indicated that a large proportion of these
genes (21 out of 68) were either muscle specific or associated with
muscle development and differentiation (see Table 1 for the list of
muscle relevant genes). Most of these genes (16 out of 21) were up
regulated upon C2C12 differentiation (Blais et al., 2005).
Interestingly, expression of these genes was unchanged in similar
experiments performed with siRNAs that decrease only the full-
length protein (the changes affecting all these mRNA were
classified as non significant, whereas JMJD2A mRNA was found
decreased by 3.4 fold, data not shown), suggesting that they are
specifically regulated by DN-JMJD2A. To confirm these findings,
we analyzed the expression of several of the affected genes (Actc1,
Tnni1, Ttn, Myog, Ckm) by reverse transcription followed by qPCR.
We found that a siRNA against both forms of JMJD2A (sie9)
strongly decreased expression of all of these genes, whereas a
siRNA against the full-length isoform only (sie3-2) had no effect,
although they both decreased similarly the expression of full-length
JMJD2A (Figure 3B). These data confirm the DNA microarray
analysis and indicate that these muscle-specific genes are
specifically activated, either directly or indirectly, by DN-JMJD2A.
To test whether DN-JMJD2A plays a role in muscle
differentiation, we knocked down both isoforms in proliferating
C2C12 cells and examined their ability to undergo differentiation.
Proliferating C2C12 cells were electroporated with the siRNAs
against both isoforms and kept in growth medium for 24 hours
before incubating them in differentiation medium for 24 hours.
The cells were then transfected again with the same siRNA, in
order to maintain the knockdown, and kept in differentiation
medium for a further 48 hours to allow full differentiation.
Differentiation was assayed by expression of myosin heavy chain
(MHC) by immunofluorescence microscopy. MHC expression and
Figure 2. Characterization of the small isoform of JMJD2A. (A) 59 RACE was performed on mRNA extracted from differentiated C2C12 cells.
The two JMJD2A mRNAs described in Genbank are illustrated in the upper panel, with the exons labelled from 1 to 22. The various 59ends identified
by 59 RACE are shown in the lower panel. The start positions relative to the first nucleotide of the described full-length mRNA (NM_001161823.1) are
indicated on the left, and the percentage of each mRNA obtained in our experiments on the right. The +1(i1) indicates mRNAs initiating within intron
1o fJMJD2A (FL for full-length; DN for N-terminal deleted). (B) The amount of JMJD2A mRNA in total RNA prepared from C2C12 cells kept in growth
medium (GM) or in differentiation medium for 72 hours (DM) was quantified by qPCR (relative to a standard curve with known amounts of JMJD2A
gene) by using primer pairs that amplified FL-JMJD2A mRNA only (pairs 1 and 2) or FL-JMJD2A, DN1-JMJD2A and DN2-JMJD2A mRNAs (pairs 2 and 3).
Quantification was performed twice in triplicate on four independent mRNA preparations from proliferating cells and differentiated myotubes. Data
were standardised relative to 1 for primer pairs 1 (corresponding to about 10
5 molecules of JMJD2A cDNA per mg of cDNA); statistical analyses of the
observed differences are indicated (p values, student T test). (C) The expression of JMJD2A was analysed by western blotting of growing C2C12
myoblasts (GM) or after 24 hours of differentiation (DM) using the antibody recognizing both isoforms of JMJD2A (a-Cter antibody); a-tubulin was
blotted as a loading control. Cells were transfected with increasing doses (0.05, 0.1 or 0.2 mg for myoblasts, lanes 2–4; 0.2, 0.4 or 1 mg for
differentiating cells, lanes 6–8) of a vector expressing the short JMJD2A mRNA beginning at nucleotide 977 of the full-length mRNA (pCDNA3-
JMJD2A-Nu977) or with the empty vector (lanes 1 and 5). The intensities of the three bands (1, 2 and 3) produced from the pCDNA3-JMJD2ANu977
construct were quantified using ImageJ software (right panel). The data are represented as the percentage of each band relative to the total intensity
of the three bands, calculated for the first dose of Nu977 expression vector (to remain in the linear range of fluorography). (D) Schematic
representation of the JMJD2A-Nu977 mRNA with potential translation initiation codons. (E) Growing C2C12 cells were transfected with 0.1 mgo f
vector expressing FL-JMJD2A or N-terminal deletion mutants (JMJD2A-M427, JMJD2A-M584). The expression of JMJD2A was analysed by western
blotting using the antibody recognizing both isoforms of JMJD2A (a-Cter antibody).
doi:10.1371/journal.pgen.1001390.g002
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PLoS Genetics | www.plosgenetics.org 5 June 2011 | Volume 7 | Issue 6 | e1001390Figure 3. DN-JMJD2A is important for muscle differentiation and myotube formation. (A) Gene expression profiles of C2C12 cells treated
with siRNAs targeting both isoforms (sie9 or sie10, directed against exon 9 and 10 respectively) or control siRNA and differentiated for 36 h, were
analysed using Affymetrix expression arrays as described in Materials and Methods. The numbers of genes that are found down- or up-regulated in
cells transfected with siRNA targeting both isoforms compared to control (fold change .1.5 when compared to the control) are indicated. (B)
Validation of the microarray results by RT-qPCR analysis of mRNA expression of various differentiation-related genes shown in Table 1, as well as FL-
JMJD2A (using primers located in the 59 end). C2C12 cells were transfected with an siRNA targeting both isoforms of JMJD2A (sie9), a siRNA targeting
only FL-JMJD2A (sie3-2, directed against exon3) or a control siRNA (sictl) and then induced to differentiate for 36 hours. mRNA levels were
standardized according to gapdh mRNA levels, and calculated relative to 1 for cells transfected by the control siRNA. (C) C2C12 cells were transfected
with siRNAs targeting both isoforms of JMJD2A (sie9 and sie10) or control siRNA (sictl). After 72 hours of differentiation, cells were stained for
JMJD2A in Muscle Differentiation
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with the siRNAs that interfered with both isoforms (Figure 3C),
but not by a siRNA that interfered with only FL-JMJD2A or by
the control siRNA (Figure 3D). Western blotting showed that, in
addition to MHC, myogenin expression was also impaired
specifically by the siRNA targeting both isoforms (Figure 3E).
These findings agree with those obtained from analysis of the
expression of these differentiation markers by RT-qPCR
(Figure 3B). Together, these data indicate that DN-JMJD2A is
required for muscle differentiation at a step before myogenin
expression.
The Myog promoter is a specific target of DN-JMJD2A
Since DN-JMJD2A functions upstream of myogenin expression
in the control of C2C12 myoblast cell differentiation, and Myog is a
master gene regulating muscle differentiation, we reasoned that
the Myog promoter might be an important target of DN-JMJD2A.
To investigate this possibility, we performed chromatin immuno-
precipitation (ChIP) on chromatin from both proliferating and
differentiating C2C12 cells by using an antibody against the C-
terminus of JMJD2A, which recognizes both isoforms, and the
immunoprecipitated Myog promoter was quantified by qPCR.
(The amylase promoter was used as a negative control since the
amylase gene is not expressed in muscle cells.) We found the Myog
promoter specifically in JMJD2A-ChIPed chromatin from differ-
entiating C2C12 cells within 24 hours of differentiation
(Figure 4A), a time at which most cells already expressed
myogenin (as observed by immunofluorescence microscopy; data
not shown). By contrast, in proliferating cells, in which myogenin
is not expressed, the signal from the Myog promoter was just above
or below the threshold of detection in some experiments). No
signal from the amylase promoter was observed (Figure 4A). The
amount of dimethylated H3K9 (H3K9me2) associated with the
Myog promoter in proliferating cells was higher than in
differentiating cells (Figure 4B); this decrease in differentiating
cells is not due to changes in nucleosome occupancy (Figure S3).
No change in the amount of H3K9me2 was observed at the
GAPDH promoter, used as a control. Thus, binding of JMJD2A
(whether FL-JMJD2A, DN- JMJD2A or both) to the Myog
promoter correlates with demethylation of H3K9me2 and
transcriptional activation of the gene.
To test whether the Myog promoter is a specific target of DN-
JMJD2A, we performed ChIP with the antibody against the C-
terminus of JMJD2A following transfection of siRNAs that
interefere specifically either only with FL-JMJD2A or with both
isoforms. We found that JMJD2A binding to the Myog promoter
was significantly reduced in cells transfected with an siRNA (e9)
targeting both isoforms, but was not affected by an siRNA
targeting only FL-JMJD2A (e3-2; Figure 4C). By contrast, this e3-
2 siRNA decreased the signal from the Tpm2 promoter (Figure S4),
Table 1. Genes associated with muscle differentiation and development (gene ontology analysis; Figure 2B) that were down-
regulated in cells transfected by siRNA targeting both isoforms of JMJD2A.
Tnnc2 troponin C2, fast 24.8898516
Myl1 myosin, light polypeptide 1 24.3695893
Ckm creatine kinase, muscle 23.976595
Myog myogenin 23.6869516
Tnni1 troponin I, skeletal, slow 1 23.3599658
Tnni2 troponin I, skeletal, fast 2 23.2088106
Tnnt3 troponin T3, skeletal, fast 23.0840454
Tnnt2 troponin T2, cardiac 22.9699507
Erbb3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 22.8317823
Acta1 actin, alpha 1, skeletal muscle 22.6396954
Unc4b unc-45 homolog B (C. elegans) 22.3936517
Mef2c myocyte enhancer factor 2C 22.2935529
Actc1 actin, alpha, cardiac 21.9588187
Ckb creatine kinase, brain 21.915279
Tmod1 tropomodulin 1 21.8805943
Ttn titin 21.7811661
Ednra endothelin receptor type A 21.7055933
Tpm3 tropomyosin 3, gamma 21.6838151
Chrnd cholinergic receptor, nicotinic, delta polypeptide 21.6777709
Dok7 docking protein 7 21.6551543
Akt2 thymoma viral proto-oncogene 2 | similar to serine/threonine kinase 21.5684415
Snf1lk SNF1-like kinase 21.5214148
The fold change in gene expression is indicated for cells treated with siRNA against JMJD2A compared to cells treated with control siRNA.
doi:10.1371/journal.pgen.1001390.t001
immunofluorescence microscopy by using an antibody against myosin heavy chain (MHC) and DAPI. (D) As in C, but C2C12 cells were transfected
with siRNA targeting FL-JMJD2A only (sie3-2) or control siRNA (sictl). (E) Western blots of total protein extracts prepared from C2C12 cells treated as in
C and D, showing myogenin, myosin heavy chain (MHC) and a-tubulin.
doi:10.1371/journal.pgen.1001390.g003
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using an antibody specific for FL-JMJD2A (see Figure 5D). These
data indicate that the Myog promoter is a direct target of the DN-
JMJD2A isoform and probably accounts for its role in C2C12
differentiation of C2C12 myoblasts.
Genome-wide analysis of JMJD2A targets
We wanted to identify other genes that may be targets of DN-
JMJD2A, however, without an antibody specific for the DN-
JMJD2A isoform, we could not ChIP this isoform independently of
FL-JMJD2A. Since DN-JMJD2A increases during differentiation,
whereas FL-JMJD2A does not (Figure 1B), we decided to search
by ChIP for genes that were bound by JMJD2A in differentiated
C2C12 cells but not in undifferentiated cells. Immunoprecipitated
DNA fragments were amplified and hybridized to a microarray
covering about 20,000 mouse gene promoters (ChIP-on-chip
methodology). Hybridization and bioinformatics analysis allowing
identification of bound regions were done by Nimblegen using the
Roche Nimblescan software. We scored promoters as bound by
JMJD2A if a binding peak (FDR p,0.01) was identified between
22000 and +500 bp from the transcription start site in at least
three of four independent experiments. We found JMJD2A bound
to 1498 genes in proliferating cells and 1181 in differentiated cells
(see Table S2 for the complete list of JMJD2A-bound promoters).
Of note, we did not identify the Myog promoter in this analysis
although we know from the experiments described above
(Figure 4A) that it is bound by JMJD2A, suggesting that we may
have missed some JMJD2A target genes in our analysis. When we
used a slightly less stringent analysis, we did find the Myog
promoter among the promoters bound by JMJD2A specifically in
myotubes (p,0.05; data not shown). Subsequent analysis by ChiP
and qPCR on selected genes, however, indicated that, although
Figure 4. DN-JMJD2A is recruited to the myogenin promoter. (A) ChIP assays were performed on C2C12 cells before (0 h) or after 24, 48 or
72 hours of differentiation by using an anti-JMJD2A antibody (+)( a-Cter antibody), or no antibody (2). Myog and Amy2 promoters were quantified by
qPCR. The data shown indicate ChIP efficiency as a proportion of the input. Position of the primers used are indicated (B) ChIP analysis of the Myog
and Gapdh promoters immunoprecipitated by using anti-H3K9me2 antibody (aH3K9me2, +), or no antibody (2) on chromatin prepared from
proliferating (GM) or differentiating (72 hours) C2C12 cells (MT), as quantified by qPCR. Results represent ChIP efficiency according to input. (C) C2C12
myoblasts were electroporated with an siRNA targeting both isoforms of JMJD2A (e9), a siRNA targeting the full-length JMJD2A only (e3-2) or a
control siRNA (ctl). Twenty-four hours later, cells were placed in differentiation medium for one day. ChIP experiments were performed as in (A). The
data represent ChIP efficiency (%) relative to the amount of Myog promoter immunoprecipitated by the anti-JMJD2A antibody.from control siRNA
electroporated cells.
doi:10.1371/journal.pgen.1001390.g004
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analysis did not reflect the actual variation in JMJD2A occupancy
in myotubes versus myoblasts. We thus concentrated on the lists of
genes shown in Table S2.
We found 485 genes bound by JMJD2A in differentiated cells
but not in proliferating cells (Figure 5A and Table S2) that are
candidates for specific targets of DN-JMJD2A. From this list, we
selected eight genes for further analysis by ChIP and qPCR (Tnnc1,
Hfe2, Zfp238, Ttn, Tpm2, Fyn, cdkn1a and myl6; Figure 5C and
Figure S5). All these genes either bound by JMJD2A specifically in
myotubes or were more enriched in mature myotubes than in
growing myoblasts. We also analyzed by ChiP and qPCR three
genes identified in the ChIP-on-chip approach bound by JMJD2A
specifically in proliferating cells (cdc6, Id3 and cnnb2) and found
they were indeed preferentially bound by JMJD2A in proliferating
cells. We conclude that our ChIP-on-chip experiments identified
bona fide targets of JMJD2A and that the genes included in the
Venn diagram represent JMJD2A target genes preferentially
enriched in either growing myoblasts (GM), differentiated
myotubes (MT) or both (Figure 5A). Gene ontology analysis of
the 485 genes preferentially bound in myotubes indicated that they
are mainly involved in gene regulation and signaling (Figure 5B),
consistent with a role of JMJD2A in controlling cell fate. To
confirm that these genes are bound by DN-JMJD2A, we
performed ChIP experiments on chromatin from proliferating or
differentiated cells by using an antibody that recognizes only the
full-length isoform (a-Nter antibody; Figure S6). Specific enrich-
ment by using this antibody was too low to perform accurate
ChIP-on-chips experiments, and we analyzed by qPCR the
binding of FL-JMJD2A to promoters of the previously validated
genes. FL-JMJD2A bound specifically to all the genes we tested
except Hfe2, but not to the amylase promoter used as a negative
control (Figure 5D and Figure S5). There was no significant
difference in the signals from myoblasts and myotubes. These data
suggest that recruitment of DN-JMJD2A accounts, at least in part,
for the increase in total JMJD2A binding detected with the
antibody that recognizes both isoforms. We verified this conclusion
for the Tnnc1 promoter by knocking down JMJD2A with an
siRNA against both isoforms or an siRNA against only FL-
JMJD2A: the siRNA against both isoforms decreased JMJD2A
binding to the promoter, whereas the siRNA against FL-JMJD2A
only did not (Figure S7).
Previous transcriptional profiling studies of differentiating
C2C12 cells found that expression of the eight genes we validated
by qPCR is induced during differentiation [24,25].
To evaluate the impact of DN-JMJD2A binding on global gene
expression, we compared our genome-wide JMJD2A-binding data
with mRNA expression profiles of differentiating C2C12 cells
previously reported by Blais and collaborators (Figure 5E). The
fold change in transcripts levels in myotubes versus myoblasts was
assigned to the genes specifically bound by JMJD2A. We found
that the genes that were specifically bound by JMJD2A in
myotubes (a group enriched in genes targeted by DN-JMJD2A)
had increased mRNA levels during differentiation, compared to
the genes bound by JMJD2A in myoblasts only (GM) or in both
situations (GM/MT). These data show that a subset of JMJD2A-
binding genes are targeted by DN-JMJD2A in myotubes and this
correlates with their transcriptional activation, as previously
observed for Myog (see Figure 1 and Figure 4A). This suggests
that DN-JMJD2A functions as a transcriptional co-activator at
certain promoters.
DN-JMJD2A allows the removal of repressive chromatin
marks
To understand the mechanism by which DN-JMJD2A promotes
transcription, we first focused on the Myog promoter, which we
identified as a direct target of DN-JMJD2A (Figure 4). We
transfected differentiating C2C12 cells with siRNAs against both
JMJD2A isoforms or against FL-JMJD2A only and analyzed the
Myog promoter for various histone modifications: depletion of
JMJD2A resulted in increased H3K9me2 and H3K9me3 and
decreased H3 pan-acetylation (Figure 6A). Similar data were
obtained for H3K9me2 and H3K9me3 at the Tnnc1 promoter
(Figure S7), which is also bound specifically by DN-JMJD2A
(Figure S7). This indicates that DN-JMJD2A regulates histone
H3K9 methylation and histone H3 acetylation levels at some
muscle-specific promoters (such as the Myog promoter) during
muscle differentiation. The differentiation-linked increase in DN-
JMJD2A levels and the subsequent increase in promoter-bound
protein are probably responsible, at least in part, for changing the
chromatin at muscle-specific genes from a repressive to an
activating state during terminal differentiation, allowing transcrip-
tional activation of the genes.
To investigate directly whether DN-JMJD2A counteracts
silencing of muscle-specific promoters, we used a myogenic
conversion assay in which non-muscle cells are converted into
muscle cells by expression of the myogenic transcription factor
MyoD. During this process, the chromatin containing muscle
genes shifts from a silent to an active state. We transfected mouse
C3H10T1/2 fibroblasts with MyoD to induce muscle conversion
and used the a-Cter antibody against JMJD2A in ChIP assays to
test whether JMJD2A was recruited to the Myog promoter
(Figure 6B). We found JMJD2A bound to the Myog promoter
one day after passage into differentiation medium, and remained
at that same level one day later. (No binding was detected at the
amylase promoter, used as a negative control.) Thus, JMJD2A is
recruited to the Myog promoter during the process of myogenic
conversion. We next investigated whether DN-JMJD2A would
potentiate myogenic conversion. NIH3T3 cells were transfected
with an expression vector encoding MyoD either alone or in
combination with an expression vector producing the endogenous
small mRNA beginning at nucleotide +977 (JMJD2A-Nu977),
which can encode DN-JMJD2A (see Figure 2C). Twenty-four
hours after transfection, cells were shifted to differentiation
Figure 5. Genome-wide analysis of JMJD2A-associated promoters. (A) ChIP-on-chip analysis (as described in Text S1) of chromatin from
proliferating C2C12 cells (GM), or after 72 hours of differentiation (MT). ChIP assays were performed as in Figure 4 by using the anti-JMJD2A antibody
recognizing both isoforms (a-Cter antibody). Numbers of JMJD2A targets in proliferatng (GM) or differentiated (MT) cells are represented on the Venn
diagram. (B) Gene ontology analysis of genes bound specifically by JMJD2A in differentiating cells. (C) Validation by qPCR of selected genes identified
by ChIP-on-chip analysis. Results represent ChIP efficiency according to input. (D) MT-specific genes analysed in (C) were subjected to ChIP analysis
with chromatin prepared as in (A) by using the anti-JMJD2A antibody recognising FL-JMJD2A only (a-Nter antibody). Results represent ChIP efficiency
according to input. (E) Distribution of expression data from Blais et al., 2005 according to the binding of JMJD2A. Box plots illustrate the genes bound
specifically in differentiating cells (MT), in proliferative cells (GM) or in both conditions (GM/MT). The ratio of mRNA expression between myotubes
and myoblasts are plotted. The bottom and top of the box correspond to the 25% and 75% cut off respectively, the band is the median, the dash
represents the mean value of the group and whiskers correspond to the 5
th and the 95
th percentiles. Statistical analyses of observed differences are
indicated (p values, student T test).
doi:10.1371/journal.pgen.1001390.g005
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microscopy for expression of MyoD, myogenin and myosin heavy
chain (MHC). As estimated by the percentage of MyoD-positive
cells that co-expressed myogenin or MHC, most cells converted to
muscle 48 h after passage into differentiation medium, irrespective
of the presence of JMJD2A-Nu977 mRNA expression vector
(Figure 6C). Myogenic conversion was significantly enhanced,
however, by JMJD2A-Nu977 mRNA overexpression at the 24 h
point, with a 2.5-fold increase in cells expressing myogenin
(p,0.02), and a 3-fold increase in cells expressing the late
differentiation marker myosin heavy chain (p,0.01) (Figure 6C).
To see if this pro-myogenic activity of JMJD2A-Nu977 mRNA
was isoform-specific, we performed similar assays by co-expressing
HA-tagged FL-JMJD2A or JMJD2A-M584 (which encodes a
protein very similar in size to DN-JMJD2A; see Figure 2) with
MyoD. In addition to MyoD, we stained cells either for myogenin
or for HA-JMJD2A and MHC (see Figure S8 for typical images).
We observed that 70–80% of cells stained for both MyoD and the
HA epitope (data not shown). Co-staining for MyoD and
myogenin was performed on cells that had been differentiating
for 12, 24 and 48 hours. Twelve hours after passage into
differentiation medium, the percentage of cells that were positive
for myogenin was much greater in the cells expressing JMJD2A-
M584 than in the cells transfected with MyoD alone, whereas
there was little difference between the cells expressing FL-JMJD2A
and the cells transfected with MyoD alone (Figure 6D). Similarly,
in cells expressing MyoD alone 24 h after the shift into
differentiation medium about 5% of MyoD-positive cells expressed
MHC. This percentage was unchanged in cells co-expressing HA-
FL-JMJD2A, but enhanced more than two-fold in cells co-
expressing JMJD2A-M584 (Figure 6E). We conclude that DN-
JMJD2A is a positive regulator of MyoD-induced differentiation
and functions by favoring the transition of muscle-specific
promoters from a repressed to an active state.
JMJD2A is reported to interact with another histone demethy-
lase JMJD2C [26]. To test whether DN-JMJD2A retains this
binding ability, we transfected U2-OS osteosarcoma cells with
expression vectors for HA-JMJD2C and either FL-JMJD2A or
JMJD2A-M584. We immunoprecipitated JMJD2C and found
both FL-JMJD2A and JMJD2A-M584 co-immunoprecipitated
(Figure 6F), indicating that JMJD2A-M584 retains the ability to
interact with JMJD2C. This suggests that DN-JMJD2A favors
H3K9 demethylation by physically interacting with the catalyti-
cally active JMJD2C-demethylase. Consistent with this, we found
that depletion of JMJD2C by using specific siRNAs (see Figure S9
for the characterization of JMJD2C siRNA) recapitulates the
effects of DN -JMJD2A inactivation on induction of the Myog and
Ckm genes (Figure 6G).
Discussion
We report here the existence of an isoform of JMJD2A (DN-
JMJD2A) that is expressed during skeletal muscle differentiation
and is required for this process. Moreover, we identify the Myog
promoter as a specific target of this isoform and demonstrate that
it mediates demethylation of histone H3 at residue K9 at this
promoter. Our findings suggest a model in which expression of
DN-JMJD2A and its consequent binding to the Myog promoter
mediates derepression of the Myog gene, a key event during the
terminal differentiation of skeletal muscle, by promoting demeth-
ylation of the promoter.
A small isoform of JMJD2A is upregulated during muscle
differentiation
This new isoform of the JMJD2A demethylase we identify here
lacks the N-terminal part of the full-length protein, which contains
the demethylase domain. We show that in C2C12 cells, it is
produced from a mRNA that initiates at exon 8. We found no
description in several databases (Genbank, UCSC) of alternative
splicing of the JMJD2A gene that might give rise to the DN-
JMJDA variant, suggesting that an internal promoter might give
rise to the shorter mRNA, which may be regulated in a
differentiation-dependent manner. Moreover, initiation through
an internal promoter would be consistent with the description of a
short RNA in the GENBANK database. Note however that the 59
end we identified by 59RACE (nucleotide 977 of the full-length
sequence) is upstream of that described in the GENBANK
database for the short RNA. Our data from using exon-specific
siRNA to knock-down JMJD2A are consistent with the interpre-
tation that nucleotide 977 constitutes the transcription start site:
only siRNAs targeting exons downstream of exon 9 decreased
both JMJD2A-FL and DN-JMJD2A expression and inhibited
differentiation.
Endogenous DN-JMJD2A protein is certainly very similar
(although perhaps not strictly identical) to JMJD2A initiating at
Met584 (JMJD2A-M584), since the two proteins migrate at very
similar molecular weights on SDS-PAGE and behave similarly in
enhancing MyoD-induced muscle differentiation of non-muscle
Figure 6. DN-JMJD2A enables the removal of a repressive chromatin state. (A) C2C12 myoblasts were transfected with an siRNA targeting
both isoforms of JMJD2A (e10), a siRNA targeting the full-length only (e3-2) or a control siRNA (ctl). Twenty-four hours later, cells were placed in
differentiation medium for one day. Chromatin was prepared and subjected to ChIP using an anti-H3K9me2 antibody (left), anti-H3K9me3 antibodies
(middle) or an anti-H3panAc antibody (right). Myog promoter DNA was quantified by qPCR. Results represent ChIP efficiency according to input. (B)
C3H10T1/2 cells were transfected with 1 mg of pEMSV-MyoD or empty pEMSV as a control. Twenty-four hours later, they were placed in
differentiation medium for 48 hours. Myog and Amy2 promoters in the ChIPs with anti-JMJD2A antibody (a-Cter antibody, +) or no antibody (2) were
quantified by qPCR. Results represent ChIP efficiency according to input. (C) NIH3T3 cells were transfected with plasmids encoding MyoD (pEMSV-
MyoD) and JMJD2A-Nu977 (pCDNA3-JMJD2A-Nu977). After 24 and 48 hours of differentiation, expression of MyoD, myogenin and myosin heavy
chain (MHC) was analysed by immunofluorescence microscopy. The data represent the percentage of MyoD-expressing cells that were also positive
for myogenin (left) or MHC (right). The number of cells counted in each condition is indicated above the histograms. (D) NIH3T3 cells were
transfected with plasmids encoding MyoD (pEMSV-MyoD, 0.5 mg), and 0.3 mg of FL-JMJD2A-HA (full-length), JMJD2A-M584-HA (N-terminal deletion
mutant) or empty vector, as indicated, and then incubated in differentiation medium for 12, 24 or 48 hours. Expression of MyoD, HA and myogenin
was analysed by immunofluorescence microscopy. Quantification represents the percentage of MyoD-expressing cells that were also positive for
myogenin. The number of cells counted for each condition is indicated above the histograms. (E) As in (D), except that cells were transferred to
differentiation medium for 24 hours before being stained for MyoD, HA and MHC. (F) U2OS cells were transfected with the indicated expression
vectors. Fourty-eight hours after transfection, total protein extracts were prepared and immunoprecipitated with an anti-HA antibody. Inputs and
immunoprecipitates were western blotted with antibodies against HA or JMJD2A. (G) C2C12 cells were transfected with an siRNA targeted against
JMJD2C (C) or a control siRNA (ctl), and kept in growth medium (0 h) or transferred to differentiation medium for 24 or 48 hours. Myog and Ckm
mRNA expression were quantified by RT-qPCR, standardized according to gapdh mRNA levels, and calculated relative to 1 in proliferating cells
transfected by the control siRNA.
doi:10.1371/journal.pgen.1001390.g006
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produced from the Nu977 mRNA. When overexpressed in C2C12
cells, JMJD2A-Nu977 mRNA (but not the full-length construct) is
translated from three distinct initiator codons encoding methio-
nine residues 317, 427 and 584. This probably reflects the so-
called ‘leaky scanning of ribosomes’ mechanism described recently
by Calkhoven and collaborators [27]. This mechanism is
controlled by specific signal transduction pathways and results in
an accurate ratio of CEBP isoforms critical for cell fate control
[27]. Although the intermediate forms of JMJD2A are observed
only upon overexpression of the JMJD2A-Nu977 mRNA, a ‘leaky
scanning of ribosomes’ mechanism might participate in the
production of the DN-JMJD2A isoform. Alternate but not
mutually exclusive explanations could be that DN-JMJD2A is
produced through an ‘IRES’-type mechanism requiring a special
structure adopted by the 59 end of the nu977 mRNA, or by limited
proteolysis of a larger protein. In agreement with this latter
hypothesis, there is no initiator codon that would give rise to a
protein with precisely the molecular weight of DN-JMJD2A.
Whatever the mechanism, it is regulated in a differentiation-
dependent manner, since the expression of DN-JMJD2A increases
with differentiation although expression of JMJD2A-Nu977
mRNA does not, and overexpression of JMJD2A-Nu977 produces
much more DN-JMJD2A in differentiating cells than in prolifer-
ating cells.
DN-JMJD2A is essential for differentiation and acts as an
activator
We show that the Myog promoter is a direct target of DN-
JMJD2A. Recruitment of DN-JMJD2A correlates with Myog
transcriptional activation at the onset of differentiation, suggesting
that its acts as a transcriptional activator. Our evidence that
inactivation of DN-JMJD2A by specific siRNAs affects the
induction of Myog transcription during muscle differentiation
supports this conclusion, as does the significant association
between myotube-specific targets, identified by our ChIP-on-chip
approach, and genes induced during differentiation [24,25]. FL-
JMJD2A has been described previously as a co-repressor of both
ASCL2- [12] and E2F-targeted genes [13], in association with N-
CoR and Rb respectively, suggesting that DN-JMJD2A may have
a dominant negative effect on FL-JMJD2A. This is unlikely
because siRNA knockdown of FL-JMJD2A does not noticeably
affect the differentiation process or myogenin expression. These
observations suggest that DN-JMJD2A might function indepen-
dently of FL-JMJD2A by recruiting specific partners. One might
imagine, for example, that FL-JMJD2A folds in such a way that
binding sites for partner proteins in the C-terminal part of the
protein are masked by the N-terminal sequences, a masking that
would not occur for the DN-JMJD2A isoform.
Role of DN-JMJD2A on the Myog promoter
The requirement of DN-JMJD2A for differentiation may be
explained by its role on myogenin expression. Myogenin is a key
effector of muscle differentiation and is required for late
differentiation events [16]. We show that DN-JMJD2A directly
regulates the Myog gene, being recruited to its promoter
concomitantly with transcriptional activation in both C2C12 cells
and MyoD-converted fibroblasts. Although this latter finding
suggests that MyoD might target DN-JMJD2A to the Myog
promoter, we found no interaction between DN-JMJD2A and
MyoD. Moreover, the fact that genes identified in our ChIP-on-
chip analysis are not enriched in MyoD-targeted genes argues
against a role for MyoD in this process [16]. DN-JMJD2A contains
a Tudor domain in its C-terminal part [28] that might recruit the
protein to its target genes by interacting with methylated H3K4, a
modification enriched in the promoter region of active genes,
including Myog [20]. H3K4 methylation, being generally associ-
ated with RNA Polymerase II-dependent gene activation [29],
other mechanisms must be involved in recruiting DN-JMJD2A
specifically to its target promoters. The mechanisms controlling
recruitment of DN-JMJD2A to the Myog promoter are likely
critical for myoblasts to undergo terminal differentiation and
deserve further analysis to understand how JMJD2A discriminates
between its target genes. As we found that MEF2A or MEF2C
expression is required for DN-JMJD2A recruitment to the Myog
promoter, MEF2 may be part of this process.
Although the molecular mechanisms by which DN-JMJD2A
activates gene expression are still unclear, we have shown that its
recruitment to the Myog promoter is required for demethylating
H3K9, an event previously shown to correlate with Myog
activation. H3K9 methylation at the Myog promoter is catalysed
by Suv39h1/KMT1A associated with MyoD [23]. This process is
positively regulated by the protein kinase p38-c that favors the
association of KMT1A with MyoD by phosphorylating MyoD at
Ser199/200. As a result, levels of methylated H3K9 at the Myog
promoter increase and both muscle differentiation and MyoD-
induced myogenic conversion of fibroblasts are impaired [22].
Thus, methylation of H3K9 is a central to Myog gene repression in
myoblasts. It impedes premature entry into the differentiation
process and allows expansion of undifferentiated cells, a process
that has to be tightly controlled during both muscle development
and regeneration. We show that demethylation of H3K9 at the
myoblast-to-myotube transition depends on DN-JMJD2A since
neither accurate Myog induction nor H3K9 demethylation was
observed in DN-JMJD2A depleted cells.
Because DN-JMJD2A lacks a demethylase domain, it must
recruit another H3K9-specific demethylase. Our findings, together
with previously published data, indicate that this demethylase
might be JMJD2C: DN-JMJD2A physically interacts with
JMJD2C and depletion of JMJD2C recapitulates the effects of
DN-JMJD2A depletion. H3K9me3 is the preferred substrate of
JMJD2C [3,7], although we show here that DN-JMJD2A is
important for demethylation of both H3K9me3 and H3K9me2.
When recruited to the Myog promoter, JMJD2C might also
demethylate H3K9me2, as it does when it is overexpressed [3,26].
Alternatively, another K9me2-specific demethylase, such as LSD1,
might be involved. LSD1 was recently found to target the Myog
promoter [30].
Another important epigenetic regulator of muscle differentia-
tion, MITR/HDRP also lacks a catalytic domain; it comprises the
non-catalytic N-terminal region of HDAC9 and is generated by
alternative splicing [31]. MITR is highly expressed in skeletal
muscle [32]; it is involved in repressing MEF2-dependent genes
through histone deacetylation of their promoters by recruiting
other deacetylases [33]. This example illustrates the importance of
variants of chromatin modifying enzymes and, in particular, of
isoforms that are deficient in enzymatic activity. Strikingly,
isoforms of many other epigenetic regulators have been identified
or are suspected to exist. Of note, the LSD1 gene was recently
shown to produce four alternatively spliced isoforms, some of
which are specifically expressed in neurons and play roles in
neurite morphogenesis [34]. A study by Lois and collaborators
[35] indicates that 49% of chromatin modifiers have alternative
spliced variants and that in more than 59% of cases, splicing
affects either the catalytic domain or the interaction domain. The
importance of isoforms of chromatin modifying enzymes may be
explained by the existence of multimolecular complexes contain-
ing many chromatin modifying activities: by incorporating
JMJD2A in Muscle Differentiation
PLoS Genetics | www.plosgenetics.org 13 June 2011 | Volume 7 | Issue 6 | e1001390catalytically active or defective isoforms of a given enzyme, these
complexes may specify distinct histone codes at their target sites,
leading to different transcriptional outcomes.
Materials and Methods
Cell culture
The C2C12 skeletal myoblast cell line was cultured under
standard conditions in DMEM-F12 supplemented with 15% FCS
(Gibco). C3H10T1/2 were maintained in MEM supplemented
with 15% FCS. NIH3T3 and U2-OS cells were grown in DMEM
supplemented with 10% FCS (Gibco). To induce differentiation,
cells were placed in differentiation medium (DMEM supplement-
ed with 1.5% horse serum (Invitrogen)). Human skeletal muscle
satellite cells were a gift from Gilles Carnac (Montpellier, France)
and were cultured as previously described [36].
JMJD2A constructs, transfection, and electroporation
Details of the construction of FL-JMJD2A and N-terminal
deletion mutants will be provided upon request. Cells were grown
in six-wells plates and transfected by using Reagent+/Lipofecta-
mine (Invitrogen) according to the manufacturer’s instructions.
One microgram of mixed plasmids was used for each transfection.
In control experiments, 60–70% of NIH3T3 cells and 40–50% of
C3H10T1/2 cells transfected with pEGFPN1 (Clontech) ex-
pressed GFP. For siRNA transfection, 4610
6 C2C12 myoblasts
were electroporated with double-stranded siRNA (purchased from
Eurogentec or Dharmacon and described in Text S1) at a final
concentration of 8 mM by using an eletroporation device (Amaxa
AG, Cologne, Germany) according to the manufacturer’s
instructions. Differentiated cells were transfected by using
oligofectamine (Invitrogen).
Western blotting
Cells were lysed for western blotting by incubating them with
Laemmli sample buffer (63 mM Tris pH 6.8, 8% glycerol, 2.5%
SDS, bromophenol blue, 5% ß-mercaptoethanol) for 5 min at
85uC to denature proteins. Western blots were performed using
standard procedures and antibodies were used at the following
concentrations: rabbit polyclonal anti-Cter JMJD2A 0.4 mg/mL
(A300861A, BethylLab), rabbit polyclonal anti-Nter JMJD2A
0.1 mg/mL (HPA007610, Sigma), mouse monoclonal anti-myo-
genin 0.4 mg/mL (F5D, Santa-Cruz), mouse monoclonal anti-a-
tubulin 0.1 mg/mL (T6199, Sigma), mouse monoclonal anti-MHC
0.1 mg/mL (05–716, Upstate), mouse monoclonal anti-HA diluted
1/1000 (HA11 Babco, Covance). Peroxidase-conjugated second-
ary antibodies were purchased from Amersham.
Immunofluorescence microscopy
Cells were fixed by adding formaldehyde to a final concentra-
tion of 3.7% in PBS and permeabilized in PBS containing 0.5%
Triton X100. The fixed and permeabilized cells were incubated at
4uC overnight with primary antibodies at the following concen-
trations: rabbit polyclonal anti-Nter JMJD2A 0.1 mg/mL
(HPA007610, Sigma), mouse monoclonal anti-myogenin 0.5 mg/
mL (F5D, Santa-Cruz), rabbit polyclonal anti-MyoD 0.5 mg/mL
(C-20, Santa-Cruz), mouse monoclonal anti-HA 1/1000e (HA11,
Covance), mouse monoclonal anti-myosin heavy chain 0.2 mg/mL
(05–716, Upstate). Fluorochrome-conjugated secondary antibodies
were purchased from Invitrogen. Observations were carried out
with a fluorescence microscope (DM; Leica, Wetlar, Germany)
equipped with a cooled charge-coupled device camera, and images
were acquired using the MetaVue imaging system (Universal
Imaging Corp., West Chester, PA).
Co-immunoprecipitation experiments
Plasmids encoding untagged forms of FL-JMJD2A or JMJD2A-
M584 either alone or together with a HA-tagged form of JMJD2C
(kindly provided by K. Helin, BRIC Copenhagen) were
introduced into U2OS cells by using an electroporation device
(Amaxa AG) according to the manufacturer’s instruction at a ratio
of 2 mg of plasmid for 10
6 cells. Fourty-eight hours after
transfection, cells were lysed in IP buffer (10 mM Tris pH 8,
0.4% NP40, 300 mM NaCl, 10% glycerol, 1 mM DTT, anti-
protease (Roche), anti-phosphatase (Sigma) inhibitors). Lysates
were diluted using one volume of dilution buffer (10 mM Tris
pH 8, 0.4% NP40, 5 mM CaCl2, 2 U/mL RQ1 DNAse
(Promega)) and then incubated with anti-HA antibodies coupled
to agarose beads (Sigma) overnight at 4uC. Beads were washed
four times with IP buffer, eluted with Laemmli sample buffer
without ß-mercaptoethanol and analyzed by western blotting.
Total RNA extraction and reverse transcription
Total RNA was extracted from cells by using the RNeasy mini
kit (Qiagen). Five hundred nanograms of RNA were reverse-
transcribed for 50 min at 42uCi na2 0 mL reaction volume
containing 0.5 mM dNTPs, 0.5 mg of random primers, 10 mM
DTT, 1X AMV RT buffer, 40 U of RNasin and 10 U of AMV
Reverse Transcriptase (Promega). Samples were incubated for
15 min at 70uC to stop the reaction. Samples were analyzed by
qPCR by using the primers described in Text S1 on a CFX96 real-
time system device (Biorad) using the platinium SYBR Green
qPCR SuperMix (Invitrogen). For quantification of JMJD2A
isoforms, RT-qPCR was performed by including a dilution curve
of JMJD2A plasmid from 1 pg to 0.1 fg corresponding to 110000
to 11 JMJD2A mRNA molecules, allowing us to estimate the exact
number of molecules per mg of total mRNA isolated either from
myoblasts or myotubes.
Expression array analysis
100 ng of total RNA for each condition was subjected to
cleanup, reverse transcription, amplification and labelling accord-
ing to the manufacturer’s instructions (GeneChip whole transcript
sense target labelling assay, Affymetrix). Raw data were processed
using Genespring GX 10.0 analysis software (Agilent technologies
Inc, Santa Clara, CA). Briefly, after normalization using the RMA
algorithm, a t-test statistical analysis was carried out to select genes
whose expression changed significantly compared to control (p-
value ,=0.05) in three independent experiments. Genes were
considered as regulated by JMJD2A when the average fold change
relative to control was higher than 1.5. Clustering was performed
according to gene ontology by using DAVID Bioinformatics
Resources 6.7 (http://david.abcc.ncifcrf.gov) and manual cura-
tion.
59RACE
59RACE experiments were carried out on 10 mg of total mRNA
extracted from differentiated cells, following the manufacturer
instructions (First choice RLM-RACE kit, Ambion). Briefly, after
decapping and 59 dephosphorylation, an adaptor was ligated at the
59 end of the mRNA and reverse transcription was performed
using primers that hybridised with sequences in exon 11 of
JMJD2A (59-CAGACGCAGGATTCACAGAA-39). 59ends were
then amplified by two rounds of PCR with primers that hybridised
with sequences in the adaptor and in exon 9 of JMJD2A (round 1:
59-AGAGCTCGCTCTGACTGACC-39, round 2: 59-TGGGC-
AGAGTGTGGTCAATA-39). PCR products were cloned by
using the pGEM-T Easy Vector kit (Promega) and sequenced.
JMJD2A in Muscle Differentiation
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Chromatin immunoprecipitation assays (ChIP) were performed
as previously described [37]. For JMJD2A ChIP, 100 mg and
300 mg of chromatin were immunoprecipitated with antibodies
directed against the C-terminal region (A300861A, BethylLab,
1 mg/mL) or N-terminal region (HPA007610, Sigma, 1 mg/mL) of
JMJD2A respectively. Ten micrograms and 5 mg of chromatin
were used in ChIP experiments with antibodies against
H3K9me2/H3K9me3 (Ab1220-100 Abcam 1 mg/mL, 07–462
Upstate 1 mg/mL) and H3-pan-acetyl (6599 Upstate 1 mg/mL),
respectively. Samples were analyzed by qPCR by using the
oligonucleotides described in Text S1.
ChIP-on-chip analysis
ChIP-on-chip analyses were performed by NimbleGen on a
mouse promoter array (MM8_RefSeq_promoter and MM8_
Deluxe_Promoter_HX1; NimbleGen, Roche). The description of
this analysis is given in Text S1. Bound genes were clustered
according to gene ontology by using DAVID Bioinformatics
Resources 6.7 (http://david.abcc.ncifcrf.gov) and manual curation.
Supporting Information
Figure S1 Sequences alignment. Sequences of the full-length
mouse JMJD2A mRNA (NM_001161823.1) and a shorter isoform
(AK136085.1) were obtained from GENBANK and align to those
of DN1-JMJD2A and DN2-JMJD2A 59-ends described in our
study, using the multalin software (http//multalin.toulouse.
inra.fr/multalin ; Multiple sequence alignment with hierarchical
clustering" F. CORPET, 1988, Nucl. Acids Res., 16 (22),10881-
10890).
Found at: doi:10.1371/journal.pgen.1001390.s001 (0.11 MB PDF)
Figure S2 Knock-down of JMJD2A does not decrease JMJD2B
or JMJD2C. C2C12 cells were transfected with the indicated
siRNAs. mRNA were extracted, reverse transcribed and the
amounts of JMJD2A, JMJD2B and JMJD2C cDNAs were
quantified by qPCR and standardized relative to gapdh.
Representative experiments are shown.
Found at: doi:10.1371/journal.pgen.1001390.s002 (0.02 MB PDF)
Figure S3 Activation of the Myog promoter is not associated
with a detectable decrease in nucleosome occupancy. C2C12 cells
were induced to differentiate for 72 hours and subjected to a
ChIP experiment using 2 different anti-histone H3 antibodies, or
no antibody as indicated. The amount of Myog promoter in the
ChIPs was quantified by qPCR. A representative experiment is
shown.
Found at: doi:10.1371/journal.pgen.1001390.s003 (0.03 MB PDF)
Figure S4 FL-JMJD2A is recruited to the Tpm2 promoter.
C2C12 cells were transfected with siRNAs targeting full-length
JMJD2A only (sie3-2) or control siRNA (sictl). 24 h later, cells
were shifted to differentiation medium for one day. Chromatin
was prepared and subjected to a ChIP using anti-CTerJMJD2A
antibody (ChIP-Ab, +), or no antibody (2). The Tpm2 promoter
was quantified by qPCR.
Found at: doi:10.1371/journal.pgen.1001390.s004 (0.03 MB PDF)
Figure S5 Validation of JMJD2A targets identified by ChIP-on-
chips. Hfe2, Cdkn1a, Zfp238, Ttn and Fyn genes were selected from
the list of target genes identified as specifically bound in myotubes
by ChIP-on-chips to be further analyzed by a classical ChIP
approach using antibodies directed against either the carboxy-
terminal end (a-CterJMJD2A, panel A) or N-terminal part (a-
NterJMJD2A, panel B) of JMJD2A. ChIP were performed with
chromatin from either growing (GM) or differentiated C2C12 cells
(MT).
Found at: doi:10.1371/journal.pgen.1001390.s005 (0.09 MB PDF)
Figure S6 Characterisation of the antibody directed against the
N-terminal part of JMJD2A. Antibodies recognizing both isoforms
of JMJD2A (a-Cter antibody) or the full-length protein only (a-Nter
antibody) were tested by western blot on extracts from C2C12 cells
over-expressing JMJD2A full length (FL-JMJD2A) or a Nterminal
deletion mutant (JMJD2A-M427). The a-Nter antibody was tested
by immunofluorescence in cells transfected by a siRNA targeting
exon 10 of JMJD2A (sie10) or a control siRNA (ctl).
Found at: doi:10.1371/journal.pgen.1001390.s006 (0.31 MB PDF)
Figure S7 DN-JMJD2A targets the Tnnc1 promoter. A) C2C12
cells were transfected with siRNA targeting either exon 9 or exon
3-2, induced to differentiate and subjected to a ChIP experiment
using a-CTerJMJD2A antibody. The amounts of Tnnc1 promoter
in the ChIP were quantified by qPCR. A representative
experiment is shown. The ChIP signal is decreased by the siRNA
targeting both isoforms (sie9) but not by the siRNA targeting the
full-length only (sie3-2), indicating that the Tnnc1 promoter is
mainly bound by DN-JMJD2A. B) Same as in A, except that ChIP
was performed using anti H3K9me2 (left) or anti H3K9me3 (right)
antibody.
Found at: doi:10.1371/journal.pgen.1001390.s007 (0.03 MB PDF)
Figure S8 Typical images of MyoD-converted cells. A) NIH3T3
cells were transfected with MyoD alone or together with plasmids
encoding FL-JMJD2A or JMJD2A-M584. Following 24 h in
differentiation medium, cells were stained for MyoD in red and for
both MHC and the HA epitope in green. MHC is cytoplasmic
whereas HA tagged JMJD2A proteins are nuclear, allowing to
discriminate between the two signals. Arrows indicate cells
expressing both MHC and MyoD, and (*) cells that express both
MyoD, MHC and HA. Note that one cell is stained for both MHC
and HA, but does not show detectable levels of MyoD.
Bar=10 mm. B) Cells were treated as in A except they were kept
in differentiation medium for 12 h and stained for MyoD in red
and myogenin in green. Arrows indicate cells that express both
MyoD and myogenin. Bar=10 mm.
Found at: doi:10.1371/journal.pgen.1001390.s008 (2.78 MB PDF)
Figure S9 Characterisation of the siRNA targeting JMJD2C.
C2C12 cells were transfected with a siRNA targeting JMJD2C (C)
or a control siRNA (ctl). mRNAs were extracted, reverse-
transcribed and the amounts of Jmjd2c and Jmjd2a were quantified
by qPCR and calculated relative to gapdh. A representative
experiment is shown.
Found at: doi:10.1371/journal.pgen.1001390.s009 (0.03 MB PDF)
Figure S10 MEF2A-C expression is required for JMJD2A
recruitment to the myogenin promoter. C2C12 cells were
transfected with a siRNA targeting MEF2A and MEF2C or a
control (ctl) siRNA. Cells were then induced to differentiate and
subjected to a ChIP using the anti-CTerJMJD2A antibody. The
amount of Myog (left) or Tpm2 (right) promoters in the ChIP were
quantified by qPCR. A representative experiment is shown.
Found at: doi:10.1371/journal.pgen.1001390.s010 (0.03 MB PDF)
Table S1 List of genes significantly affected by the JMJD2A
siRNAs.
Found at: doi:10.1371/journal.pgen.1001390.s011 (0.03 MB
XLS)
Table S2 JMJD2A ChIP-chips analysis. Here is shown the lists
of genes bound by JMJD2A in proliferative conditions only (GM),
in differentiating conditions only (MT) or in both conditions
JMJD2A in Muscle Differentiation
PLoS Genetics | www.plosgenetics.org 15 June 2011 | Volume 7 | Issue 6 | e1001390(commons (GM-MT)). Also shown is a Gene Ontology analysis of
genes bound in differentiating conditions only (GO analysis).
Found at: doi:10.1371/journal.pgen.1001390.s012 (0.31 MB
XLS)
Text S1 Supplementary Materials and Methods.
Found at: doi:10.1371/journal.pgen.1001390.s013 (0.05 MB
DOC)
Acknowledgments
The authors would like to thank Dr G. Carnac for materials and L.
Schaeffer for helpful discussions.
Author Contributions
Conceived and designed the experiments: LV DT MV. Performed the
experiments: LV CC MV. Analyzed the data: LV FE DT MV. Wrote the
paper: DT MV.
References
1. Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, et al. (2007) New
nomenclature for chromatin-modifying enzymes. Cell 131: 633–636.
2. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, et al. (2004) Histone
demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:
941–953.
3. Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, et al. (2006) The
putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on
histone H3. Nature 442: 307–311.
4. Couture JF, Collazo E, Ortiz-Tello PA, Brunzelle JS, Trievel RC (2007)
Specificity and mechanism of JMJD2A, a trimethyllysine-specific histone
demethylase. Nat Struct Mol Biol 14: 689–695.
5. Fodor BD, Kubicek S, Yonezawa M, O’Sullivan RJ, Sengupta R, et al. (2006)
Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in
mammalian cells. Genes Dev 20: 1557–1562.
6. Klose RJ, Yamane K, Bae Y, Zhang D, Erdjument-Bromage H, et al. (2006)
The transcriptional repressor JHDM3A demethylates trimethyl histone H3
lysine 9 and lysine 36. Nature 442: 312–316.
7. Whetstine JR, Nottke A, Lan F, Huarte M, Smolikov S, et al. (2006) Reversal of
histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell
125: 467–481.
8. Wissmann M, Yin N, Muller JM, Greschik H, Fodor BD, et al. (2007)
Cooperative demethylation by JMJD2C and LSD1 promotes androgen
receptor-dependent gene expression. Nat Cell Biol 9: 347–353.
9. Agger K, Cloos PA, Christensen J, Pasini D, Rose S, et al. (2007) UTX and
JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and
development. Nature 449: 731–734.
10. Lan F, Bayliss PE, Rinn JL, Whetstine JR, Wang JK, et al. (2007) A histone H3
lysine 27 demethylase regulates animal posterior development. Nature 449:
689–694.
11. Loh YH, Zhang W, Chen X, George J, Ng HH (2007) Jmjd1a and Jmjd2c
histone H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells.
Genes Dev 21: 2545–2557.
12. Zhang D, Yoon HG, Wong J (2005) JMJD2A is a novel N-CoR-interacting
protein and is involved in repression of the human transcription factor achaete
scute-like homologue 2 (ASCL2/Hash2). Mol Cell Biol 25: 6404–6414.
13. Gray SG, Iglesias AH, Lizcano F, Villanueva R, Camelo S, et al. (2005)
Functional characterization of JMJD2A, a histone deacetylase- and retinoblas-
toma-binding protein. J Biol Chem 280: 28507–28518.
14. Shin S, Janknecht R (2007) Activation of androgen receptor by histone
demethylases JMJD2A and JMJD2D. Biochem Biophys Res Commun 359:
742–746.
15. Guasconi V, Puri PL (2009) Chromatin: the interface between extrinsic cues and
the epigenetic regulation of muscle regeneration. Trends Cell Biol 19: 286–294.
16. Cao Y, Kumar RM, Penn BH, Berkes CA, Kooperberg C, et al. (2006) Global
and gene-specific analyses show distinct roles for Myod and Myog at a common
set of promoters. Embo J 25: 502–511.
17. Sartorelli V, Caretti G (2005) Mechanisms underlying the transcriptional
regulation of skeletal myogenesis. Curr Opin Genet Dev 15: 528–535.
18. Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V (2004) The
Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal
muscle differentiation. Genes Dev 18: 2627–2638.
19. Seenundun S, Rampalli S, Liu QC, Aziz A, Palii C, et al. (2010) UTX mediates
demethylation of H3K27me3 at muscle-specific genes during myogenesis.
EMBO J.
20. Rampalli S, Li L, Mak E, Ge K, Brand M, et al. (2007) p38 MAPK signaling
regulates recruitment of Ash2L-containing methyltransferase complexes to
specific genes during differentiation. Nat Struct Mol Biol 14: 1150–1156.
21. Zhang CL, McKinsey TA, Olson EN (2002) Association of class II histone
deacetylases with heterochromatin protein 1: potential role for histone
methylation in control of muscle differentiation. Mol Cell Biol 22: 7302–7312.
22. Gillespie MA, Le Grand F, Scime A, Kuang S, von Maltzahn J, et al. (2009) p38-
{gamma}-dependent gene silencing restricts entry into the myogenic differen-
tiation program. J Cell Biol 187: 991–1005.
23. Mal AK (2006) Histone methyltransferase Suv39h1 represses MyoD-stimulated
myogenic differentiation. Embo J 25: 3323–3334.
24. Blais A, Tsikitis M, Acosta-Alvear D, Sharan R, Kluger Y, et al. (2005) An initial
blueprint for myogenic differentiation. Genes Dev 19: 553–569.
25. Moran JL, Li Y, Hill AA, Mounts WM, Miller CP (2002) Gene expression
changes during mouse skeletal myoblast differentiation revealed by transcrip-
tional profiling. Physiol Genomics 10: 103–111.
26. Shin S, Janknecht R (2007) Diversity within the JMJD2 histone demethylase
family. Biochem Biophys Res Commun 353: 973–977.
27. Calkhoven CF, Muller C, Leutz A (2000) Translational control of C/EBPalpha
and C/EBPbeta isoform expression. Genes Dev 14: 1920–1932.
28. Lee J, Thompson JR, Botuyan MV, Mer G (2008) Distinct binding modes
specify the recognition of methylated histones H3K4 and H4K20 by JMJD2A-
tudor. Nat Struct Mol Biol 15: 109–111.
29. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, et al. (2007) High-
resolution profiling of histone methylations in the human genome. Cell 129:
823–837.
30. Choi J, Jang H, Kim H, Kim S, Cho E, et al. (2010) Histone demethylase LSD1
is required to induce skeletal muscle differentiation by regulating myogenic
factors. Biochem Biophys Res Commun 401: 327–332.
31. Petrie K, Guidez F, Howell L, Healy L, Waxman S, et al. (2003) The histone
deacetylase 9 gene encodes multiple protein isoforms. J Biol Chem 278:
16059–16072.
32. Zhang CL, McKinsey TA, Olson EN (2001) The transcriptional corepressor
MITR is a signal-responsive inhibitor of myogenesis. Proc Natl Acad Sci U S A
98: 7354–7359.
33. Mejat A, Ramond F, Bassel-Duby R, Khochbin S, Olson EN, et al. (2005)
Histone deacetylase 9 couples neuronal activity to muscle chromatin acetylation
and gene expression. Nat Neurosci 8: 313–321.
34. Zibetti C, Adamo A, Binda C, Forneris F, Toffolo E, et al. (2010) Alternative
splicing of the histone demethylase LSD1/KDM1 contributes to the modulation
of neurite morphogenesis in the mammalian nervous system. J Neurosci 30:
2521–2532.
35. Lois S, Blanco N, Martinez-Balbas M, de la Cruz X (2007) The functional
modulation of epigenetic regulators by alternative splicing. BMC Genomics 8:
252.
36. Jean E, Laoudj-Chenivesse D, Notarnicola C, Rouger K, Serratrice N, et al.
(2009) Aldehyde dehydrogenase activity promotes survival of human muscle
precursor cells. J Cell Mol Med.
37. Vandromme M, Chailleux C, Escaffit F, Trouche D (2008) Binding of the
Retinoblastoma Protein Is Not the Determinant for Stable Repression of Some
E2F-Regulated Promoters in Muscle Cells. Mol Cancer Res.
JMJD2A in Muscle Differentiation
PLoS Genetics | www.plosgenetics.org 16 June 2011 | Volume 7 | Issue 6 | e1001390